167. Am J Hum Genet. 2018 Jul 5;103(1):3-18. doi: 10.1016/j.ajhg.2018.04.013. Epub2018 Jun 14.Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple PrimaryTumor Series Shows a Broad Range of Deleterious Variants and Atypical TumorPhenotypes.Whitworth J(1), Smith PS(1), Martin JE(1), West H(1), Luchetti A(1), Rodger F(1),Clark G(1), Carss K(2), Stephens J(2), Stirrups K(2), Penkett C(2), Mapeta R(2), Ashford S(3), Megy K(2), Shakeel H(1), Ahmed M(4), Adlard J(5), Barwell J(6),Brewer C(7), Casey RT(1), Armstrong R(8), Cole T(9), Evans DG(10), Fostira F(11),Greenhalgh L(12), Hanson H(13), Henderson A(14), Hoffman J(9), Izatt L(15), KumarA(16), Kwong A(17), Lalloo F(10), Ong KR(9), Paterson J(18), Park SM(8),Chen-Shtoyerman R(19), Searle C(20), Side L(4), Skytte AB(21), Snape K(13),Woodward ER(10); NIHR BioResource Rare Diseases Consortium(3), TischkowitzMD(22), Maher ER(23).Collaborators: Aitman T, Alachkar H, Ali S, Allen L, Allsup D, Ambegaonkar G,Anderson J, Antrobus R, Armstrong R, Arno G, Arumugakani G, Ashford S, Astle W,Attwood A, Austin S, Bacchelli C, Bakchoul T, Bariana TK, Baxendale H, Bennett D,Bethune C, Bibi S, Bitner-Glindzicz M, Bleda M, Boggard H, Bolton-Maggs P, Booth C, Bradley JR, Brady A, Brown M, Browning M, Bryson C, Burns S, Calleja P, CanhamN, Carmichael J, Carss K, Caulfield M, Chalmers E, Chandra A, Chinnery P, Chitre M, Church C, Clement E, Clements-Brod N, Clowes V, Coghlan G, Collins P, Cookson V, Cooper N, Corris P, Creaser-Myers A, DaCosta R, Daugherty L, Davies S, DavisJ, De Vries M, Deegan P, Deevi SVV, Deshpande C, Devlin L, Dewhurst E, Dixon P,Doffinger R, Dormand N, Drewe E, Edgar D, Egner W, Erber WN, Erwood M, Erwood M, Everington T, Favier R, Firth H, Fletcher D, Flinter F, Frary A, Freson K, Furie B, Furnell A, Gale D, Gardham A, Gattens M, Ghali N, Ghataorhe PK, Ghurye R,Gibbs S, Gilmour K, Gissen P, Goddard S, Gomez K, Gordins P, Graf S, Gräf S,Greene D, Greenhalgh A, Greinacher A, Grigoriadou S, Grozeva D, Hackett S,Hadinnapola C, Hague R, Haimel M, Halmagyi C, Hammerton T, Hart D, Hayman G,Heemskerk JWM, Henderson R, Hensiek A, Henskens Y, Herwadkar A, Holden S, Holder M, Holder S, Hu F, Huis In't Veld A, Huissoon A, Humbert M, Hurst J, James R,Jolles S, Josifova D, Kazmi R, Keeling D, Kelleher P, Kelly AM, Kennedy F, Kiely D, Kingston N, Koziell A, Krishnakumar D, Kuijpers TW, Kuijpers T, Kumararatne D,Kurian M, Laffan MA, Lambert MP, Allen HL, Lango-Allen H, Lawrie A, Lear S, Lees M, Lentaigne C, Liesner R, Linger R, Longhurst H, Lorenzo L, Louka E, Machado R, Ross RM, MacLaren R, Maher E, Maimaris J, Mangles S, Manson A, Mapeta R, MarkusHS, Martin J, Masati L, Mathias M, Matser V, Maw A, McDermott E, McJannet C,Meacham S, Meehan S, Megy K, Mehta S, Michaelides M, Millar CM, Moledina S, MooreA, Morrell N, Mumford A, Murng S, Murphy E, Nejentsev S, Noorani S, Nurden P,Oksenhendler E, Othman S, Ouwehand WH, Ouwehand WH, Papadia S, Park SM, Parker A,Pasi J, Patch C, Paterson J, Payne J, Peacock A, Peerlinck K, Penkett CJ,Pepke-Zaba J, Perry D, Perry DJ, Pollock V, Polwarth G, Ponsford M, Qasim W,Quinti I, Rankin S, Rankin J, Raymond FL, Rayner-Matthews P, Rehnstrom K, Reid E,Rhodes CJ, Richards M, Richardson S, Richter A, Roberts I, Rondina M, Rosser E,Roughley C, Roy N, Rue-Albrecht K, Samarghitean C, Sanchis-Juan A, Sandford R,Santra S, Sargur R, Savic S, Schotte G, Schulman S, Schulze H, Scott R, Scully M,Seneviratne S, Sewell C, Shamardina O, Shipley D, Simeoni I, Sivapalaratnam S,Smith KGC, Sohal A, Southgate L, Staines S, Staples E, Stark H, Stauss H, SteinP, Stephens J, Stirrups K, Stock S, Suntharalingam J, Talks K, Tan Y, Thachil J, Thaventhiran J, Thomas E, Thomas M, Thompson D, Thrasher A, Tischkowitz M,Titterton C, Toh CH, Toshner M, Treacy C, Trembath R, Tuna S, Turek W, Turro E,Van Geet C, Veltman M, Vogt J, von Ziegenweldt J, Vonk Noordegraaf A, Wakeling E,Wanjiku I, Warner TQ, Wassmer E, Watkins H, Watt C, Webster N, Welch S, Westbury S, Wharton J, Whitehorn D, Wilkins M, Willcocks L, Williamson C, Woods G, WoodsG, Wort J, Yeatman N, Yong P, Young T, Yu P.Author information: (1)University of Cambridge Department of Medical Genetics, NIHR CambridgeBiomedical Research Centre, and Cancer Research UK Cambridge Centre, CambridgeBiomedical Campus, Cambridge CB2 0QQ, UK.(2)NIHR BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus,Cambridge CB2 0QQ, UK; Department of Haematology, University of Cambridge, NHSBlood and Transplant Centre, Cambridge Biomedical Campus, Cambridge CB2 0PT, UK.(3)NIHR BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus,Cambridge CB2 0QQ, UK.(4)Department of Clinical Genetics, Princess Anne Hospital, Southampton SO16 5YA,UK; North East Thames Regional Genetics Service, Great Ormond Street Hospital forChildren, London WC1N 3JH, UK.(5)Yorkshire Regional Genetics Service, Chapel Allerton Hospital, Leeds LS7 4SA, UK.(6)Department of Clinical Genetics, University Hospitals of Leicester, Leicester Royal Infirmary, Leicester LE1 5WW, UK.(7)Peninsula Clinical Genetics, Royal Devon & Exeter Hospital, Exeter EX1 2ED,UK.(8)University of Cambridge Department of Medical Genetics, NIHR CambridgeBiomedical Research Centre, and Cancer Research UK Cambridge Centre, CambridgeBiomedical Campus, Cambridge CB2 0QQ, UK; NIHR BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK; East AnglianMedical Genetics Service, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK.(9)West Midlands Regional Genetics Service and Birmingham Health Partners,Birmingham Women's and Children's Hospitals NHS Foundation Trust, Birmingham B15 2TG, UK.(10)Manchester Centre for Genomic Medicine, Division of Evolution and GenomicSciences, University of Manchester, Manchester Academic Health Science Centre,St. Mary's Hospital, Manchester M13 9WL, UK.(11)Molecular Diagnostics Laboratory, National Centre of Scientific Research"Demokritos," Athens, Greece.(12)Department of Clinical Genetics, Liverpool Women's Hospital, Liverpool L87SS, UK.(13)Department of Clinical Genetics, St. George's Hospital, London SW17 0QT, UK.(14)Northern Genetics Service, Newcastle upon Tyne Hospitals, InternationalCentre for Life, Newcastle upon Tyne NE1 3BZ, UK.(15)Department of Clinical Genetics, Guy's and St. Thomas' Hospital, London SE19RT, UK.(16)North East Thames Regional Genetics Service, Great Ormond Street Hospital forChildren, London WC1N 3JH, UK.(17)Division of Breast Surgery, University of Hong Kong, Pokfulam, Hong Kong;Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; HongKong Sanatorium and Hospital, Happy Valley, Hong Kong.(18)East Anglian Medical Genetics Service, Cambridge Biomedical Campus, CambridgeCB2 0QQ, UK.(19)Clinical Genetics Institute, Kaplan Medical Center, Rehovot 76100, Israel;Hebrew University and Hadassah Medical Center, Jerusalem, Israel.(20)Department of Clinical Genetics, Nottingham University Hospitals, CityHospital, Nottingham NG5 1PB, UK.(21)Department of Clinical Genetics, Aarhus University Hospital, Aarhus 8200,Denmark.(22)University of Cambridge Department of Medical Genetics, NIHR CambridgeBiomedical Research Centre, and Cancer Research UK Cambridge Centre, CambridgeBiomedical Campus, Cambridge CB2 0QQ, UK; NIHR BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK.(23)University of Cambridge Department of Medical Genetics, NIHR CambridgeBiomedical Research Centre, and Cancer Research UK Cambridge Centre, CambridgeBiomedical Campus, Cambridge CB2 0QQ, UK; NIHR BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK. Electronicaddress: erm1000@medschl.cam.ac.uk.Multiple primary tumors (MPTs) affect a substantial proportion of cancersurvivors and can result from various causes, including inherited predisposition.Currently, germline genetic testing of MPT-affected individuals for variants incancer-predisposition genes (CPGs) is mostly targeted by tumor type. Weascertained pre-assessed MPT individuals (with at least two primary tumors by age60 years or at least three by 70 years) from genetics centers and performedwhole-genome sequencing (WGS) on 460 individuals from 440 families. Despiteprevious negative genetic assessment and molecular investigations, pathogenicvariants in moderate- and high-risk CPGs were detected in 67/440 (15.2%)probands. WGS detected variants that would not be (or were not) detected bytargeted resequencing strategies, including low-frequency structural variants(6/440 [1.4%] probands). In most individuals with a germline variant assessed as pathogenic or likely pathogenic (P/LP), at least one of their tumor types wascharacteristic of variants in the relevant CPG. However, in 29 probands (42.2% ofthose with a P/LP variant), the tumor phenotype appeared discordant. Thefrequency of individuals with truncating or splice-site CPG variants and at leastone discordant tumor type was significantly higher than in a control population(χ2 = 43.642; p ≤ 0.0001). 2/67 (3%) probands with P/LP variants had evidence of multiple inherited neoplasia allele syndrome (MINAS) with deleterious variants intwo CPGs. Together with variant detection rates from a previous series ofsimilarly ascertained MPT-affected individuals, the present results suggest that first-line comprehensive CPG analysis in an MPT cohort referred to clinicalgenetics services would detect a deleterious variant in about a third ofindividuals.Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.DOI: 10.1016/j.ajhg.2018.04.013 PMCID: PMC6037202 [Available on 2019-01-05]PMID: 29909963 